Fanni Rencz1, Valentin Brodszky2, Márta Péntek3, Orsolya Balogh2, Eva Remenyik4, Andrea Szegedi4, Péter Holló5, Sarolta Kárpáti5, Hajnalka Jókai5, Krisztina Herszényi5, Emese Herédi4, Sándor Szántó6, László Gulácsi2. 1. Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék Budapest Fővám tér 8. 1093 Semmelweis Egyetem, Általános Orvostudományi Kar Klinikai Orvostudományok Doktori Iskola Budapest. 2. Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék Budapest Fővám tér 8. 1093. 3. Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék Budapest Fővám tér 8. 1093 Pest Megyei Flór Ferenc Kórház Reumatológiai Osztály Kistarcsa. 4. Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Bőrgyógyászati Klinika, Bőrgyógyászati Allergológiai Tanszék Debrecen. 5. Semmelweis Egyetem, Általános Orvostudományi Kar Bőr-, Nemikórtani és Bőronkológiai Klinika Budapest. 6. Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Reumatológiai Tanszék Debrecen.
Abstract
INTRODUCTION: Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. AIM: To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. METHOD: A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. RESULTS: Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively. CONCLUSIONS: Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.
INTRODUCTION:Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. AIM: To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. METHOD: A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. RESULTS: Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively. CONCLUSIONS:Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.
Entities:
Keywords:
Hungary; Magyarország; arthritis psoriatica; biological therapy; biológiai terápia; cost of illness; health related quality of life; költség; psoriasis; psoriatic arthritis; életminőség
Authors: Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek Journal: Qual Life Res Date: 2016-07-29 Impact factor: 4.147
Authors: Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147
Authors: Fanni Rencz; Ágnes Kovács; Valentin Brodszky; László Gulácsi; Zalán Németh; Gábor János Nagy; János Nagy; István Buzogány; Géza Böszörményi-Nagy; Attila Majoros; Péter Nyirády Journal: Int Urol Nephrol Date: 2015-06-21 Impact factor: 2.370